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Traumatic brain injury (TBI) results in significant disability due to cognitive deficits
particularly in attention, learning and memory, and higher-order executive functions. The
role of TBI in chronic neurodegeneration and the development of neurodegenerative
diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic
Lateral Sclerosis (ALS) and most recently chronic traumatic encephalopathy (CTE) is of
particular importance. However, despite significant effort very few therapeutic options
exist to prevent or reverse cognitive impairment following TBI. In this review, we present
experimental evidence of the known secondary injury mechanisms which contribute to
neuronal cell loss, axonal injury, and synaptic dysfunction and hence cognitive impairment
both acutely and chronically following TBI. In particular we focus on the mechanisms
linking TBI to the development of two forms of dementia: AD and CTE. We provide
evidence of potential molecular mechanisms involved in modulating Aβ and Tau following
TBI and provide evidence of the role of these mechanisms in AD pathology. Additionally
we propose a mechanism by which Aβ generated as a direct result of TBI is capable of
exacerbating secondary injury mechanisms thereby establishing a neurotoxic cascade that
leads to chronic neurodegeneration.
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TBI A GLOBAL HEALTH CONCERN
Traumatic brain injury (TBI) is a leading cause of death and dis-
ability in industrialized countries. In the US alone, more than 1.7
million TBI’s occur annually and currently, at least 5.3 million
Americans are living with a long-term or life-long disability due
to a TBI (Faul et al., 2010). The most common causes of TBI in
civilian populations are as a result of car accidents, violence (gun
and knife wounds) and falls (particularly in the elderly popula-
tion) (Faul et al., 2010). For those engaged in contact sports, mild
TBI’s in the form of a concussion (short impairment of brain
function) with or without loss of consciousness is a significant
risk.While, inmilitary population’s blast induced TBI has become
the “signature injury” of both the Iraq and Afghanistan conflicts
(Levin and Robertson, 2012).
A TBI can be classified as focal in which a direct physical
impact to the brain results in the development of a contu-
sion or an extra or sub-dural hemorrhage, or, diffuse in nature
where diffuse axonal injury is induced following rapid accelera-
tion/deceleration forces.
Traditionally, a TBI is also classified by severity level based
upon a number of criteria including: the level of conscious-
ness, the Glasgow coma scale, and the presence of post-traumatic
amnesia (Werner and Engelhard, 2007). Mild TBI which is typi-
cally characterized by short-term memory and attention impair-
ments accounts for 75–85% of all TBI’s suffered in civilian
(Faul et al., 2010) and military populations (Communications).
Recently it has become apparent that repetitive mild TBI’s,
suffered by certain vulnerable populations including athletes
involved in contact sports and military personnel can lead to
much more significant long-term emotional and cognitive dis-
abilities (Levin and Robertson, 2012).
An overarching consequence of TBI is both short and long-
term cognitive deficits. These deficits typically occur in atten-
tion, learning and memory and higher order executive functions.
Cognitive deficits post-TBI can be attributed to damage to certain
vulnerable brain regions including the medial temporal regions,
dorso-lateral prefrontal cortex as well as sub-cortical white mat-
ter tracts (McAllister, 2011). The hippocampus, which is crucial
for declarative memory formation demonstrates atrophy via MRI
in a significant proportion of patients who receive a moderate
to severe TBI (Bigler et al., 1997). Moderate to severe TBI’s are
accepted to cause long-term, persistent cognitive deficits in suffer-
ers (Dikmen et al., 2009), while mild TBI is most often associated
with short-term cognitive dysfunction that tends to resolve within
three months of injury (Levin and Robertson, 2012). However,
it is now recognized that a subset of mild TBI patients (up to
15%) develop post-concussion syndrome, this results in persis-
tent cognitive difficulties along with a host of other neurobehav-
ioral symptoms including emotional disturbances and headaches
(Levin and Robertson, 2012). Despite significant efforts few ther-
apeutic options exist to prevent or reverse cognitive dysfunction
following TBI in humans. Understanding the molecular mecha-
nisms responsible for impaired cognition after TBI will hopefully
yield new therapeutic agents.
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PRIMARY AND SECONDARY INJURIES INCURRED BY THE
BRAIN ARE RESPONSIBLE FOR COGNITIVE DYSFUNCTION
FOLLOWING TBI
The degree of cognitive dysfunction experienced following TBI is
determined by the extent of damage to the brain from both the
primary and secondary insults/injuries suffered. A direct phys-
ical impact to the brain or shear forces (due to rapid angular
acceleration/deceleration) from the primary injury causes direct
mechanical damage to neuronal and glial cells, the vascula-
ture and strains axons. The damage from the primary injury is
immediate and irreversible and as a result is only amenable to
preventative protective measures (e.g., personal protective equip-
ment). The primary insult initiates the activation of a vicious
cycle of secondary injury effects that include both systemic com-
plications and cellular injury mechanisms that arise over the
course of hours to several weeks following the primary injury.
Systemic impairments including edema, increased intracranial
pressure (ICP) and hemorrhage, all contribute to decreased cere-
bral blood flow (CBF) and impaired metabolism resulting in
ischemia. The ischemia induced by these systemic impairments
contributes to the initiation of biochemical and cellular cascades
including glutamate excitotoxicity, calcium overload, free radi-
cal generation, mitochondrial dysfunction, inflammatory events,
and pro-apoptotic gene activation. These cellular injury processes
result in neuronal cell loss through necrotic (rapid, uncontrolled)
and programmed (delayed) cell death. Programmed cell death
can occur by a number of mechanisms including apoptosis (see
reviews Zhang et al., 2005; Stoica and Faden, 2010), necroptosis
[see reviews (Christofferson and Yuan, 2010; Vandenabeele et al.,
2010)] and autophagy [see reviews (Jaeger andWyss-Coray, 2009;
Decuypere et al., 2012)]. The extent of cell loss following TBI has
been correlated with cognitive deficits and long-term prognosis in
both clinical and experimental studies (see Wakade et al., 2010).
Traditionally, axonal injury was thought to be primarily asso-
ciated with diffuse injuries. However, it has become apparent
that axonal injury in the form of axonal separation is a common
sequelae of all TBI’s and the extent of axonal injury closely corre-
lates with outcome post-TBI (see Kraus et al., 2007; Johnson et al.,
2012a). Improvements in imaging techniques have allowed the
detection of extensive white matter tract damage in even mild to
moderate cases of TBI. It was originally thought that the majority
of axonal separation occurred due to tearing and shearing of the
axons during the primary injury. However, it is now known that
TBI induced axonal degeneration is as a result of secondary acti-
vation of biochemical and cellular injury cascades (Kraus et al.,
2007).
In addition to neuronal cell loss and axonal degeneration,
impaired synaptic plasticity also contributes to cognitive dys-
function particularly in mild to moderate cases of TBI where no
overt cell loss is detected. TBI induces abnormalities in neuro-
transmitter systems (e.g., cholinergic, monoaminergic, and cate-
cholamine), which play important roles in cognition (McAllister,
2011). Impaired calcium homeostasis following TBI affects sig-
naling pathways including those of the protein kinases CaMKII
and MAPK, which play important roles in phosphorylating
downstream effectors involved in the induction of long-term
potentiation (LTP) and long-term depression (LTD), two of the
major molecular mechanisms underlying learning and memory
(Figure 1).
GLUTAMATE EXCITOTOXICITY AND INTRACELLULAR
CALCIUM OVERLOAD INITIATE BIOCHEMICAL CASCADES
LEADING TO NEURONAL DEATH FOLLOWING TBI
Increased extracellular glutamate level is the primary initiating
event responsible for intracellular calcium overload and sec-
ondary damage following TBI (Arundine and Tymianski, 2004).
Increased extracellular glutamate is derived from a number of
sources. Mechanical damage from the primary injury compro-
mises cell membranes resulting in the release of glutamate into
the extracellular space. Membrane depolarization due to injury-
induced ionic imbalances can enhance vesicular release of gluta-
mate. While, injury-induced energy depletion can also lead to a
failure in extracellular glutamate uptake by ATP-dependent glial
glutamate transporters. Taken together these mechanisms result
in dramatically increased extracellular glutamate levels following
TBI (Yi and Hazell, 2006).
Excitotoxicity leads to neuronal injury in two phases. The first
phase is characterized by sodium dependent neuronal swelling
due to activation of ionotrophic glutamatergic receptors resulting
in the opening of sodium channels an influx of Na+ ions (and
Ca++ ions) an efflux of K+ ions, which is then followed by
delayed calcium dependent neuronal degeneration. The influx of
Na+ ions leads to membrane depolarization, opening voltage-
dependent calcium channels, and removing the magnesium block
on NMDA receptors causing a greater influx of calcium into the
cytosol (Mark et al., 2001). Calcium influx is further amplified
by alterations in AMPA receptor subunit composition (loss of
GluR2 subunits)making themmorecalciumpermeable (Luoet al.,
2011b). In addition to acting on ionotrophic receptors glutamate
can also activate group Imetabotropic glutamate receptors thereby
stimulatingopeningof voltage-gated calciumchannels and further
increasing calcium influx (Niswender and Conn, 2010). This
dramatic influx of calcium combined with energy failure initiates
the release of intracellular stores of calcium ions (Figure 2).
Excessive intracellular calcium levels trigger the activation of
secondary biochemical cascades, which ultimately result in the
initiation of programmed cell death and the loss of neurons and
synapses in vulnerable brain regions such as the hippocampus
producing cognitive dysfunction. Elevated intracellular calcium
initiates many cellular pathways including the activation of phos-
pholipases such as calcineurin (CaN), proteases including cal-
pains, and caspases, transcription factors including c-Fos, c-Jun,
and c-myc, nitric oxide synthase (NOS) as well as DNA degrading
endonucleases. The over-activation or overproduction of any of
these molecules can lead to the degradation of cytoskeletal com-
ponents (e.g., dendritic spine loss), mitochondrial dysfunction,
oxidative stress, and pro-apoptotic gene activation (see Ray et al.,
2002; Arundine and Tymianski, 2004; Werner and Engelhard,
2007) (Figure 2).
MODELING COGNITIVE DYSFUNCTION AND
NEURODEGENERATIONWITH EXPERIMENTAL TBI
The pathophysiology of TBI observed in humans is extremely het-
erogeneous in nature and is influenced by a number of parameters
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FIGURE 1 | Schematic representation of primary and secondary
phases of injury leading to cognitive dysfunction following TBI. The
primary injury force (direct physical impact or rotational
accelaration/decelaration) gives rise to either a focal or diffuse injury
which initiates secondary systemic complications and cellular injury
mechanisms leading to cell death, axonal injury, and impaired synaptic
plasticity contributing to the cognitive dysfunction observed following a
TBI. The extent of cell death and axonal injury correlate strongly with
neurological outcome following brain injury. TBI induced impairments in
synaptic plasticity characterized by impaired long-term potentiation (LTP)
and enhanced long-term depression (LTD), two well-known molecular
mechanisms controlling memory formation, also contribute to cognitive
dysfunction particularly in mild TBI where no overt cell loss is detected
despite chronic cognitive deficits being observed.
associated with the primary injury including the type and sever-
ity of trauma and the brain regions affected as well as additional
confounders such as age and gender. All of these factors coa-
lesce to initiate the secondary injury processes responsible for
cognitive dysfunction and neurodegeneration (Saatman et al.,
2008; Margulies et al., 2009). Moreover, the interplay between
the cellular injury pathways add an additional element of com-
plexity to identification of molecular mechanisms of cognitive
impairment. Hence, experimental animal models of TBI that
replicate the human condition are invaluable for the study of these
mechanisms.
TBI-induced cognitive dysfunction has been successfully mod-
eled using methods of experimental TBI including weight-drop,
rotational/acceleration injury, fluid percussion injury (FPI), con-
trolled cortical impact (CCI) and more recently penetrating
ballistic and blast models of TBI (see Albert-Weissenberger and
Siren, 2010; Marklund and Hillered, 2011; O’Connor et al., 2011;
Xiong et al., 2013). The bulk of research modeling cognitive dys-
function has been carried out in rodents using FPI and CCI
models of TBI. Studies have reproducibly demonstrated spatial
and working memory deficits, which can persist for more than a
year in some cases (Pierce et al., 1998; Dixon et al., 1999; Zohar
et al., 2003; Xiong et al., 2013). Rodent TBImodels replicate many
of the hallmarks of secondary injury identified in human TBI
patients including microglial and astrocytic activation along with
secretion of pro-inflammatory cytokines and chemokines, axonal
injury, glutamate excitotoxicity, cortical spreading depression,
mitochondrial dysfunction, free radical generation and neurode-
generation (see Albert-Weissenberger and Siren, 2010).
Experimental TBI in rodents has revealed that neurons within
the CA3 region of the hippocampus are particularly vulnera-
ble following injury with studies demonstrating a 60% loss of
CA3 pyramidal neurons acutely following injury (Baldwin et al.,
1997; Norris and Scheff, 2009). The CA3 pyramidal neurons
give rise to the Schaffer collaterals resulting in a partial deaf-
farentation of the CA1 regio superior dendritic field following
TBI (Scheff et al., 2005). Studies have shown that the loss of
CA3 pyramidal neurons correlates with inhibition of LTP in the
CA1 region of the hippocampus following TBI (Scheff et al.,
2005). In addition to impairing LTP, LTD is enhanced follow-
ing TBI furthering impairing learning and memory (Albensi
et al., 2000). Interestingly, it has been shown that despite the
hippocampus displaying remarkable plasticity with extensive re-
innervation occurring following TBI, synapse replacement does
Frontiers in Aging Neuroscience www.frontiersin.org July 2013 | Volume 5 | Article 29 | 3
Walker and Tesco Abeta-mediated neurodegeneration following TBI
FIGURE 2 | Pathophysiological mechanisms of cell death following
TBI. In moderate to severe cases of TBI the extent of cell death strongly
correlates with cognitive outcome. Following injury cell death can occur
by two main pathways, necrosis and programmed cell death. Necrotic
cell death is a rapid uncontrolled form of cell loss mediated primarily by
calpains and spilled lysosomal cathepsins and contributes to the
inflammatory response following TBI. In comparison programmed cell
death mechanisms including apoptosis, necroptosis or autophagy occur in
a delayed fashion following TBI. A key initiating event in the cell death
pathways is TBI induced glutamate excitotoxicity due to damaged cell
membranes, enhanced vesicular release of glutamate and impaired
glutamate reuptake by glia resulting in increased glutamate levels at the
synapse. Increased extracellular glutamate levels activate ionotrophic and
metabotropic glutamate receptors leading to intracellular calcium overload
and activation of secondary cellular injury mechanisms including calcium
sensitive phosphatase and protease activation, mitochondrial oxidative
stress, inflammation and proapoptotic gene activation initiating cell death
pathways.
not necessarily correlate with an improvement in spatial learn-
ing in rodents (Scheff et al., 2005). Taken together with data
from studies demonstrating extended alterations in hippocampal
synaptic transmission in rodents subjected to TBI (up to 15 days),
the prolonged cognitive deficits observed following TBI may be
the result of subtle yet chronic alterations in synaptic plasticity
beyond overt neuronal loss (Miyazaki et al., 1992; Reeves et al.,
1995; D’Ambrosio et al., 1998; Sick et al., 1998; Albensi et al.,
2000; Sanders et al., 2000; Witgen et al., 2005; Wakade et al.,
2010; Zhang et al., 2011). Activation of calcium dependent
phosphatases (calcineurin) and proteases (calpains) following
TBI have been demonstrated to impair neurotransmission by
mediating the retraction and collapse of dendritic spines, ulti-
mately leading to spine loss and cognitive deficits (Posmantur
et al., 1997; Saatman et al., 2010; Gao et al., 2011; Campbell et al.,
2012a). Additionally, TBI has been shown to induce abnormalities
in a number of neurotransmitter systems, which play important
roles modulating cognition. The random activation of glutamate
receptors following TBI is a fundamental element of the injury
process. Following the initial flood of extracellular glutamate and
the resultant hyperexcitability there is a delayed downregulation
of glutamate receptors that can last for many days in experi-
mental models (see reviews Arundine and Tymianski, 2004; Luo
et al., 2011b). Such alterations in glutamatergic signaling are
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implicated in impaired induction of LTP and enhanced induction
of LTD following TBI. The reduction in inhibition along with the
hyperexcitability observed in the hippocampus following TBI is
evidence of impaired GABAergic neurotransmission. Studies have
demonstrated reduced GABA receptor binding and alterations
in GABA receptor subunit composition following experimen-
tal TBI (Gibson et al., 2010). Importantly, impaired GABAergic
signaling has been implicated the development of epileptogenic
events post-injury (see review Imbrosci and Mittmann, 2011).
TBI has also been implicated in the chronic impairment of cholin-
ergic neurotransmission. Following injury a massive release of
Acetylcholine (ACh) occurs resulting in a downregulation in
muscarinic acetycholine receptor binding affinity, which is then
followed by a prolonged depression in ACh release. Studies have
shown that the ability of the cholinergic system to respond
to an evoked release of ACh is chronically impaired follow-
ing experimental cortical injury (see review Tenovuo, 2006).
Additionally, alterations in dopaminergic signaling have been
identified in the prefrontal cortex and striatum of rodents fol-
lowing experimental TBI. These alterations include changes in
tissue levels of dopamine and the dopamine transporter, along
with acute increases in the dopamine D1 receptor level along
with delayed increases in tyrosine hydroxylase synthesis, the rate-
limiting enzyme involved in catecholamine synthesis (see review
Bales et al., 2009).
ATTENUATING SECONDARY INJURY BIOCHEMICAL
CASCADES CONFERS NEUROPROTECTION AND IMPROVES
COGNITIVE OUTCOME FOLLOWING EXPERIMENTAL TBI
Therapeutic strategies to prevent the spatial memory deficits
observed in rodents following experimental TBI have focused on
intervening in the secondary injury cascade to prevent neuronal
loss, axonal injury and improve synaptic plasticity. A primary
initiating event in this cascade is glutamate-mediated excito-
toxicity. It is mediated primarily through abnormal activation
of the highly calcium permeable NMDA receptors resulting in
intracellular calcium overload and induction of neurotoxic cas-
cades. As a result, therapeutic interventions have focused on
antagonizing NMDA and to a lesser extent AMPA receptors in
animal models of TBI. Pharmacological blockade using MK-801
(Phillips et al., 1998; Biegon et al., 2004; Han et al., 2009), CP-
89-113 (Okiyama et al., 1998), memantine (Rao et al., 2001)
and telampenal (Belayev et al., 2001) resulted in neuropro-
tection and improved cognition following experimental TBI.
However, due to the important role glutamate plays in normal
excitatory signaling this therapeutic strategy has largely failed in
human clinical trials. Recently, Feng et al. (2011) described an
alternate strategy to prevent glutamate-mediated excitotoxicity
by targeting glutamate release rather than antagonizing gluta-
matergic receptors. They demonstrated that reducing extracellu-
lar glutamate levels using the N-acetylaspartylglutmate (NAAG)
peptidase inhibitor (ZJ-43) greatly improved cognitive perfor-
mance following experimental TBI in rats by preventing the
hydrolysis of the NAAG peptide neurotransmitter, which reg-
ulates synaptic release of glutamate (Feng et al., 2011). This
strategy augments an endogenous control mechanism for glu-
tamate release but requires further investigation to determine
if it demonstrates advantages over glutamatergic receptor
antagonism.
Mitochondrial dysfunction also plays an important role in
cognitive dysfunction following TBI. Deficits in mitochondrial
bioenergetics occur rapidly following experimental TBI (<1 h)
and can persist for up to 14 days (Xiong et al., 1997; Gilmer
et al., 2009). The significant structural and functional damage
mitochondria undergo following TBI is mediated primarily by
glutamate-mediated excitotoxicity resulting in mitochondrial cal-
cium overload. Following trauma, excessive intracellular calcium
can exhaust the calcium buffering ability of mitochondria lead-
ing to the formation of the mitochondrial permeability transport
pore (mPTP). A consequence of mPTP formation is the loss of
membrane potential resulting in an uncoupling of electron trans-
port fromATP production and the release of pro apoptotic factors
(cytochrome c and AIF) and activation of cell death pathways (see
Cheng et al., 2012). A number of studies have shown that block-
ing key components of mPTP formation in rodent experimental
models of TBI using cyclosporin A and cyclosporin analogues
such as NIM811 dramatically improves mitochondrial function
and cognitive performance (Scheff and Sullivan, 1999; Sullivan
et al., 1999; Readnower et al., 2011).
Additionally, mPTP formation results in the production of
reactive oxygen species (ROS) generating free radicals and causing
oxidative damage to cells. Oxidative damage plays an important
role in cell death pathway activation, axonal injury and impaired
synaptic plasticity leading to cognitive deficits post-TBI (Wu et al.,
2006; Ohta et al., 2013) (see Cheng et al., 2012). ROS gener-
ated by dysfunctional mitochondria and reactive nitrogen species
generated through glutamate-mediated NMDAR activation can
form the highly reactive species peroxynitrite, which is toxic to
cells. Peroxynitrite induces protein nitration, lipid peroxidation
and DNA fragmentation activating caspase independent apop-
totic cell death (Ansari et al., 2008). A number of studies have
demonstrated that attenuating oxidative stress can improve cog-
nitive function following TBI (Wu et al., 2004, 2006; Hou et al.,
2012; Ohta et al., 2013).
TBI-induced neuroinflammation is a highly complex pro-
cess with both neuroprotective and neurotoxic components.
Following TBI, astrocytes and microglia resident in the CNS
respond to the disruption of the blood brain barrier (BBB)
becoming activated. Activated glia secretes a range of proinflam-
matory cytokines and chemokines that are neurotoxic. Levels
of the proinflammatory cytokines Tumor necrosis factor (TNF),
Interleukin 1β (IL-1β) and Interleukin-6 (IL-6) have been shown
to increase dramatically within hours of a TBI (Lloyd et al., 2008).
Binding of cytokine receptors activates numerous intracellular
signaling pathways including c-Jun N-terminal kinase (JNK), p38
mitogen activated protein kinase (p38/MAPK) and extracellular
signaling-related kinase (ERK) which play key roles in synaptic
plasticity (Pearson et al., 2001). Furthermore, cytokine bind-
ing can promote cell death through the activation of caspases
(Wallach, 1997). In addition to secreting cytokines microglia have
been demonstrated to secrete additional substances including
ROS and nitrogen species along with glutamate, which under
normal conditions play an important role in neural transmis-
sion but when microglia become chronically activated under
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inflammatory conditions further contributes to neuronal cell
death (see review Block et al., 2007). The neuroinflammatory
response initiated following TBI is highly persistent with inflam-
mation detected for at least one year post-injury in animal
models and many years in humans (Ramlackhansingh et al.,
2011; Acosta et al., 2013). Neuroinflammation and chronic
microglial activation have been shown to play an important
role in cognitive dysfunction post-TBI. Importantly, the persis-
tence of the inflammatory response following TBI provides an
important therapeutic window in order to prevent neurodegen-
eration. Administration of compounds that prevent microglial
activation (Sauerbeck et al., 2011; James et al., 2012) and/or sup-
press the release of proinflammatory cytokines and chemokines
(Lloyd et al., 2008; Clausen et al., 2009) have been demonstrated
to dramatically improve long-term cognitive function following
experimental TBI.
An endpoint of these biochemical cascades is the induction
of programmed cell death. Neuronal loss has been demonstrated
to correlate with cognitive deficits and prognosis both clinically
and experimentally following TBI (see Wakade et al., 2010). Two
phases of neuronal cell death occur following TBI. Immediately
following the primary injury, necrosis, an uncontrolled pas-
sive form of cell death occurs, which, is then followed by a
delayed wave of programmed cell death. Necrotic cell death is
mediated by calpains and spilled lysosomal cathepsins and con-
tributes to the inflammatory response witnessed following TBI
(Artal-Sanz and Tavernarakis, 2005; McAllister, 2011). While the
cell death that occurs immediately following the primary injury
through mechanical damage and rapid activation of necrosis is
not amenable to therapeutic intervention, the delayed nature of
programmed cell death provides an important therapeutic win-
dow. Strategies aimed directly at inhibiting apoptosis (Knoblach
et al., 2002; Abrahamson et al., 2006; Bao et al., 2011; Li et al.,
2011a; Piao et al., 2012), necroptosis (You et al., 2008) and
autophagy (Luo et al., 2011a) have been shown to be neuroprotec-
tive following experimental TBI reducing cell loss and improving
outcome includingmotor function and spatial memory. Evidence
suggests that following TBI multiple cell death pathways may be
activated independently and function in parallel. Additionally,
there may be cross talk between cell death pathways (Piao et al.,
2012; Wang et al., 2012). In light of this, Piao et al., 2012 recently
published a study demonstrating that therapeutic targeting of
multiple cell death pathways, in this case both caspase-dependent
and independent forms of apoptosis provides superior neuropro-
tection than those aimed only at a single pathway (Piao et al.,
2012).
In order to translate these experimental successes into clin-
ically relevant therapies to ameliorate cognitive dysfunction
following TBI, we must understand the underlying molecular
pathways that mediate these secondary injury cascades.
TBI, THE AGING BRAIN AND COGNITIVE DYSFUNCTION
The aged brain is much more vulnerable to the effects of TBI
and outcome is much worse in older subjects who receive a brain
injury. There is accumulating evidence that TBI accelerates the
onset of cognitive decline leading to dementia (Sullivan et al.,
1987; Gedye et al., 1989; Schofield et al., 1997; Nemetz et al.,
1999). Aging is one of the most significant risk factors for the
development of dementia of the Alzheimer’s Type. It is possi-
ble that TBI combines with normal ageing processes resulting
in the exacerbated cognitive decline witnessed in some people
who suffered a TBI (Moretti et al., 2012). Experimental studies
have replicated the greatly impaired functional and cognitive out-
come observed in aged humans following TBI using aged rodents
(Onyszchuk et al., 2008; Sandhir et al., 2008). Interestingly, cal-
cium homeostasis is significantly more dysregulated in the hip-
pocampus of aged animals than younger animals following TBI
which could lead to prolonged activation of secondary injury cas-
cades and increased cell death (Osteen et al., 2001). In keeping
with this theory studies have demonstrated exacerbated inflam-
matory responses including exaggerated microglial and astrocytic
activation associated with increased numbers of dying neurons;
higher levels of oxidative damage, reduced expression of neuro-
protective genes, as well as increased mitochondrial dysfunction,
particularly in the synapses of aged rodents following brain
injury (Sandhir et al., 2004, 2008; Shah et al., 2006; Shao et al.,
2006; Anderson et al., 2009; Gilmer et al., 2010; Itoh et al.,
2013). Additionally, signaling pathways crucial to the formation
of LTP are significantly more impaired in older animals post-
TBI. Moderate to severe experimental TBI is known to impair
the cAMP-PKA pathway which plays a key role in the induction
of LTP (Titus et al., 2013). However, a recent study demonstrated
that in aged animals evenmild TBI is sufficient to cause significant
decreases in cAMP levels in the hippocampus but not in young
animals. This reduction in cAMP coincides with reduced CA1
hippocampal LTP, which is partially reversable with Rolipram, a
drug which increases cAMP levels (Titus et al., 2013). Analysis
of the effects of TBI on aged animals may explain age related
deficits in synaptic plasticity and the reason why older patients
demonstrate prolonged cognitive impairment following mild TBI
compared to younger patients.
TRAUMATIC BRAIN INJURY AND CHRONIC
NEURODEGENERATION
It is generally accepted that TBI can precipitate on-going pro-
cesses/cascades and in vivo conditions that lead to chronic
neurodegeneration and the development of neurodegenerative
diseases such as Parkinson’s disease (PD), Alzheimer’s disease
(AD), Amyotrophic lateral sclerosis (ALS), and the newly clas-
sified entity chronic traumatic encephalopathy (CTE) (see Uryu
et al., 2007; Lehman et al., 2012). The potential for head trauma
to precipitate conditions amenable to chronic neurodegenera-
tion is not a new phenomenon. It has been well known that
repetitive head trauma could lead to cognitive decline since the
phenomenon of dementia pugilistica (DP) or “punch–drunk”
syndrome was first described in boxers in 1928 (Martland, 1928).
Today DP is refered to as a variant of CTE due to the accumu-
lation of hyperphophorylated tau in the brain and is a classic
example of repetitive mild TBI leading to dementia later in
life. Evidence from histopathological and biochemical analysis
of biopsy material from TBI patients and sufferers of neurode-
generative disorders indicates that the molecular pathways of
TBI induced neurodegeneration and those of neurodegenerative
disease must overlap. Material obtained from both conditions
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show remarkably similar pathology and accumulation of identi-
cal proteins implicated in disease pathogenesis including amyloid
precursor protein (APP), β-secretase (BACE1), presenilin 1 (PS-
1), tau and α-synuclein (Chen et al., 2004; Uryu et al., 2007;
Sivanandam and Thakur, 2012).
In recent years there has been increased media attention on
the long-term effects of brain trauma. This has primarily focused
on trauma in form of concussion suffered by certain vulnerable
populations such as athletes engaged in contact sports. A recent
study of National Football League (NFL) players demonstrated
that football players have neurodegenerative mortality rates three
times higher than the general US population and four times the
national rate for the neurodegenerative sub-categories of AD and
ALS (Lehman et al., 2012). The risk of cognitive impairment
appears to increase with the number of insults suffered, with one
study demonstrating a 5-fold increase in mild cognitive disorders
and a 3-fold prevalence of significantmemory problems in players
who suffered three or more concussions (Guskiewicz et al., 2005).
While the case for repetitive insults causing chronic neurode-
generation and cognitive impairment is solid, there is increasing
evidence that a single moderate to severe head trauma is suffi-
cient to cause chronic neurodegeneration and the development
of a neurodegenerative disorder such as AD in some individuals
(Mortimer et al., 1985, 1991; Graves et al., 1990; Molgaard et al.,
1990; O’Meara et al., 1997; Salib and Hillier, 1997; Schofield et al.,
1997; Guo et al., 2000; Plassman et al., 2000; Fleminger et al.,
2003; Johnson et al., 2012b).
The molecular mechanisms responsible for chronic neurode-
generation, cognitive impairment, and increasing a persons risk
of developing a neurodegenerative disorder following a TBI
remain largely unknown. It is apparent that single moderate to
severe episodes of head trauma appear to be associated with the
pathological accumulation of the Aβ peptide, while mild repet-
itive traumas are associated with increased tau phosphorylation
(Dekosky et al., 2010). In this review we will focus on exper-
imental evidence of potential molecular mechanisms that have
been uncovered linking TBI to the development of two forms of
dementia: AD (characteristic Aβ and tau pathology) and CTE (a
tauopathy).
TBI-INDUCED AD PATHOLOGY
AD is the one of the most common neurodegenerative diseases,
and accounts for approximately 70% of all cases of dementia.
The key pathological hallmarks of AD are extracellular senile
plaques composed of neurotoxic Aβ peptide and intracellular
neurofibrillary tangles (NFT) composed of hyperphosphory-
lated tau. Aβ is a 38–43 amino acid peptide that is generated
by the sequential cleavage of the amyloid precursor protein
(APP) by β-secretase (BACE1) and γ-secretase enzymes. Tau is
a microtubule-associated protein that under normal conditions
plays an important role in stabilizing axonal microtubules. While
it is clear that both Aβ and tau play important roles in AD pathol-
ogy, under the amyloid cascade hypothesis it is generally accepted
that Aβ generation and amyloid plaque deposition are the initiat-
ing events in the pathology of AD and precede NFT formation.
AD is a highly complex disease, the vast majority of cases are
sporadic and most likely arise from the complex interactions of
multiple genes with each other as well as the environment (Reitz
et al., 2011). TBI is one of the strongest environmental risk fac-
tors for the development of AD and there is significant evidence
that a single event of moderate to severe TBI is sufficient to
increase the risk of developing AD. A pathological link between
TBI and the risk of later development of AD was established by
the demonstration of Aβ plaques and intra-axonal accumulation
of Aβ in 30% of patients who died acutely after suffering a severe
TBI (Roberts et al., 1991, 1994; Gentleman et al., 1997; Smith
et al., 2003a,b; Ikonomovic et al., 2004; Dekosky et al., 2007;
Uryu et al., 2007; Chen et al., 2009). Plaque deposition following
TBI occurred regardless of age as they were detected in children.
However, in comparison to AD in which senile plaques develop
slowly, the plaques observed in TBI patients developed rapidly
often within 2 h of injury (Roberts et al., 1991, 1994). These
observed plaques were diffuse in nature similar to very early stage
AD rather than the dense neuritic plaques observed in late stage
AD. This is despite the fact that they were predominately com-
posed of Aβ42, the aggregation prone form of Aβ (Dekosky et al.,
2007). Interestingly the appearance of plaques in TBI patients
appears to be temporally regulated, with plaques disappearing in
the months following injury (Chen et al., 2009). Whereas, analysis
of brains from TBI patients many years post injury reveals plaques
in greater numbers than in age-matched controls (Johnson et al.,
2012b). Interestingly, in keeping with the amyloid hypothesis, the
presence of NFT’s is not observed acutely following TBI, but is
observed in patients who survive many years following a single
severe episode of TBI (Johnson et al., 2012b).
Soluble Aβ levels are increased and Aβ deposition occurs
rapidly both clinically and experimentally following TBI (Johnson
et al., 2010). Increased levels of the key components of amy-
loidogenic cascade APP, BACE1, and PS-1 have been identified
in the damaged axons from human TBI patients (Uryu et al.,
2007; Chen et al., 2009). Enhanced APP immunoreactivity is used
as a diagnostic marker for axonal damage post-TBI. The intra-
axonal accumulation of Aβ in white matter does not fit with the
typical picture of Aβ generation in ADwhich is preferentially lim-
ited to the gray matter. Chen and colleagues proposed a model
to explain the increased synthesis of Aβ following TBI induced
axonal damage. They proposed that the disruption of axonal
transport that occurs following injury results in the accumula-
tion in axonal bulbs of APP and the APP-secretases responsible
for its processing into Aβ thereby facilitating the increased gen-
eration of Aβ. Following lysis and axonal breakdown this Aβ
could be released into the brain parenchyma where it could be
sequestered into plaques (Chen et al., 2004). Aβ accumulation in
axonal bulbs has since been demonstrated by other researchers in
both humans and animals following trauma (see Johnson et al.,
2012a). It should be noted that while increases in APP immunore-
activity in damaged axons following TBI has been demonstrated
clinically and experimentally, whether this represents an overall
increase in total APP levels in tissue is subject to debate. We and
others failed to detect an increase in total APP levels in tissue by
western blotting in the acute phase post-injury, it may be that
while APP concentrations increase in axonal varicosities, the total
pool in tissue does not (Ciallella et al., 2002; Abrahamson et al.,
2006; Schwetye et al., 2010; Walker et al., 2012). Alternatively
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these discrepancies could arise due to differences in experimental
TBI protocols (Table 1).
Aβ GENESIS POST-TBI: A ROLE FOR BACE1
BACE1 is the key rate-limiting enzyme involved in the generation
of Aβ. BACE1 is a stress related protein and levels are elevated in
the brains of AD patients (Cole and Vassar, 2008). We and others
have demonstrated that BACE1 levels are dramatically increased
following experimental TBI and this increase coincides with ele-
vated Aβ production (Blasko et al., 2004; Loane et al., 2009;
Walker et al., 2012). Inhibition of BACE1 is therapeutic post-TBI
in rodents (Loane et al., 2009) and is being actively pursued as a
therapeutic strategy for the treatment of AD. BACE1 levels and
activity are regulated at many levels within the cell including, at
the transcriptional, translational and post-translational levels (see
Walker et al., 2012). We have recently identified a novel molecular
mechanism involving the post-translational regulation of BACE1
by the adaptor protein GGA3. We have previously shown that the
adaptor protein GGA3 plays a key role in trafficking BACE1 from
the endosomes to the lysosomes for degradation (Tesco et al.,
2007; Kang et al., 2010). Our studies demonstrate that GGA3
is capable of regulating BACE1 levels both in vitro and in vivo
and that impaired degradation of BACE1 due to caspase-3 cleav-
age of GGA3 results in dramatically increased Aβ levels in vitro
(Tesco et al., 2007; Walker et al., 2012). GGA3 levels are reduced
by 50% in the temporal cortex of AD patients concurrently with
caspase-3 activation, indicating that reduced levels of GGA3 may
play an important role in regulating BACE1 levels in the brains
of AD patients (Tesco et al., 2007). We have recently demon-
strated that caspase-3 mediated cleavage of GGA3 and its closely
related homolog GGA1, synergistically regulate BACE1 levels and
Aβ production in the acute phase (48 h) following experimen-
tal TBI in rodents. Importantly, using GGA3+/− mice we have
demonstrated that a 50% reduction in GGA3 (as has been identi-
fied in the brains of AD patients) is sufficient to cause a sustained
elevation of BACE1 levels and activity and Aβ production in sub-
acute phase (7days) of injury when GGA1 levels have returned
to normal. This is the first demonstration of a molecular mecha-
nism of BACE1 elevation following TBI. Taken together with our
data that demonstrates that GGA3 plays a key role in regulat-
ing BACE1 levels in vivo, impaired degradation of BACE1 due to
reduced levels of GGA3 represents an attractive molecular mech-
anism linking acute brain injury to chronic Aβ production and
neurodegeneration. As Aβ has been shown to be able to stimulate
caspase-3 activation (Mattson et al., 1998; Kasa et al., 2004), we
postulate that TBI induced Aβ would be expected to result in fur-
ther caspase activation leading to additional depletion of GGA1
and GGA3 and increased elevation of BACE1 and Aβwhich could
create a vicious self perpetuating cycle. This data supports the
hypothesis that subjects with lower levels of GGA3 may be at
greater risk of developing AD following TBI.
Aβ CLEARANCE MECHANISMS POST-TBI
Aβ clearance mechanisms also play an important role in the over-
all level of Aβ in the brain witnessed following TBI and in the
brains of AD patients. In addition to microglial activation a num-
ber of other naturally occurring mechanisms exist to clear Aβ
from the brain. Neprilysin, a zinc-metalloendopeptidase is the
primary scavenger of Aβ in vivo and has been shown to be upreg-
ulated following TBI. Neprilysin immunoreactivity is upregulated
for up to 3 years following TBI presumably as a neuropro-
tective mechanism. This enhanced neprilysin immunoreactivity
observed in long-term survivors of TBI was closely associated
with the absence of Aβ plaques (Chen et al., 2009). The impor-
tance of neprilysin in Aβ clearance has been demonstrated by
Iwata and coworkers who showed that endogenous Aβ increased
in a dose-dependent manner in neprilysin null mice (Iwata et al.,
2001). Importantly, neprilysin has been implicated in AD patho-
genesis with decreased levels of neprilysin observed in the brains
of AD patients (Yasojima et al., 2001a,b; Caccamo et al., 2005).
Johnson and colleagues identified a polymorphism in the pro-
moter region of the neprilysin gene that correlated with Aβ
deposition after TBI (Johnson et al., 2009). However, the role of
neprilysin polymorphisms in Aβ pathogenesis following TBI and
in AD requires further investigation.
APOε is the major lipid carrier in the brain and it has
been shown to be increased both clinically and experimentally
following TBI, presumably to scavenge lipids released follow-
ing cell death and myelin breakdown (Laskowitz et al., 1998;
Iwata et al., 2005). Importantly, APOε has been shown to reg-
ulate Aβ metabolism and it has been theorized that improving
APOε function may facilitate neuronal repair and increase Aβ
clearance post-TBI. Lipidated APOε binds Aβ and delivers it to
microglia for degradation by neprilysin. The more richly lipi-
dated APOε is, the greater the clearance of Aβ (Fitz et al., 2010).
The ATP-binding cassette transporter A1 (ABCA1) plays a key
role in Aβ clearance. ABCA1 regulates cholesterol and phospho-
lipid efflux from cells to lipid poor apolipoproteins APO A-I
(plasma) and APOε (CNS) to generate high-density lipoproteins
(HDL) (Brooks-Wilson et al., 1999). APP transgenic mice with
only one functional copy of ABCA1 display significant cognitive
deficits, which correlate with the level of soluble Aβ (Lefterov
et al., 2009). Conversely increasing ABCA1’s expression phar-
macologically or genetically significantly ameliorates amyloid
Table 1 | Common pathological features in TBI and AD.
Pathology TBI (clinical and experimental) AD (human brain and transgenic mouse model)
↑Soluble Aβ and Aβ plaque deposition Walker et al., 2012; see review Johnson et al., 2010 See review Torres-Aleman, 2008; Perl, 2010
↑Tau-P and NFT’s Tran et al., 2011; Johnson et al., 2012b See review Torres-Aleman, 2008; Perl, 2010
Neuronal cell loss Baldwin et al., 1997; Wakade et al., 2010 See review Torres-Aleman, 2008; Perl, 2010
Synapse loss Wakade et al., 2010; Gao et al., 2011 Reddy and Beal, 2008; see review Arendt, 2009
Dendritic spine loss and remodeling Gao et al., 2011; Campbell et al., 2012a Knobloch and Mansuy, 2008; Hudry et al., 2012
Frontiers in Aging Neuroscience www.frontiersin.org July 2013 | Volume 5 | Article 29 | 8
Walker and Tesco Abeta-mediated neurodegeneration following TBI
pathology and improves cognitive function in transgenic mice
(see Fitz et al., 2012). A number of studies have demonstrated
that upregulation of ABCA1 using LXR agonists is neuropro-
tective improving cognitive outcome following experimental TBI
in both transgenic and non-transgenic mice (Loane et al., 2011;
Namjoshi et al., 2013). In humans, the APOε4 allele has been
shown to be associated with increased risk of developing AD,
while the APOε2 allele appears to offer some risk protection.
While, the role of APOε4 in modulating outcome following TBI
appears to be much more complex, it is generally accepted that
the presence of the APOε4 allele confers poor neurological out-
come following TBI (see Verghese et al., 2011). A recent study
by Fitz et al. (2012) demonstrated the role of ABCA1 in mod-
ulating APOε level in the presence of the APOε4 allele, which
is associated with increased AD risk. The APOε4 background
resulted in increased deposition of Aβ and impaired cognitive
function concurrent with a reduction in APOε and APOA-1
when ABCA1 was depleted by 50%, but not when the APOε3
allele was present which is not associated with increased AD risk
(Fitz et al., 2012). The reduction of APOε witnessed in ABCA1
null mice is hypothesized to be due to its increased metabolism
due to poor lipidation and stability, as mRNA levels were unaf-
fected (Wahrle et al., 2004). This study highlights an important
link between APOε4 status and reduced Aβ clearance follow-
ing TBI representing a potential mechanism leading to chronic
neurodegeneration.
It is clear that soluble Aβ levels are elevated clinically and
experimentally following TBI through an interplay of genera-
tion and clearance mechanisms. It is well known that soluble Aβ
can mediate a variety of neurotoxic functions that could hypo-
thetically be responsible for creating “feed forward” mechanisms
that following its initial increase as a result of TBI could estab-
lish a vicious neurotoxic cascade ultimately leading to chronic
neurodegeneration. This neurotoxic cascade could provide the
link between Aβ increases following acute brain injury and the
development of AD. In the following sections we will review
experimental evidence of potential mechanisms that modulate
Aβ and tau following TBI and provide evidence of the role of
these mechanisms in AD pathology.We will provide evidence that
Aβ itself is capable of mediating many of these mechanisms and
maybe the crucial factor leading to chronic neurodegeneration
following brain injury (Figure 3).
SYNAPTIC DYSFUNCTION AND LOSS CLOSELY CORRELATES
WITH COGNITIVE IMPAIRMENT FOLLOWING TBI AND IN AD
BRAIN
In addition to overt neuronal loss, synaptic dysfunction and
synapse loss are pathophysiological hallmarks of both TBI and
AD. Synaptic dysfunction/degeneration is considered one of the
most reliable markers of cognitive impairment in AD and can
be detected very early on in the disease process, as early as MCI,
the pro-dromal state of AD (Arendt, 2009). Studies have demon-
strated an 18% loss of synapses in the CA1 hippocampal region of
MCI patients, which progressed to a 55% loss in mild AD cases.
The progression of AD is marked by a progressive loss of synapses
eventually accompanied by a 10–20% loss of cortical neurons (see
Arendt, 2009). In AD, synapse loss is not always confined to dying
FIGURE 3 | Schematic representation of the proposed mechanism by
which TBI induced increases in Aβ create a vicious neurotoxic cascade
leading to chronic neurodegeneration. Soluble Aβ levels are increased
both clinically and experimentally following TBI and are known to impair
synaptic plasticity and hence cognitive function by inhibiting LTP and
enhancing LTD mechanisms of memory formation. The increased Aβ
observed following TBI presumably occurs through a combination of
increased generation and impaired clearance mechanisms. BACE1 levels are
elevated following experimental TBI and directly contribute to the observed
increases in Aβ. Caspase-3 mediated cleavage of BACE1 interacting adaptor
proteins GGA1 and GGA3 has been demonstrated to modulate BACE1
levels and Aβ production following experimental TBI. The increased Aβ
levels observed due to mechanisms including caspase mediated depletion
of GGA1 and GGA3 could theoretically create a vicious feed forward
mechanism leading to further propagation of Aβ. In vitro evidence suggests
that Aβ is capable of initiating and mediating many of the cellular injury
mechanisms that lead to programmed cell death following TBI.
neurons but can also occur in surviving neurons (Coleman and
Yao, 2003). Analysis of synaptic components from brains of AD
patients revealed decreased levels of pre-synaptic (as measured by
synaptophysin) and post-synaptic (as measured by synaptopodin
and PSD-95) proteins. Importantly, synaptic loss appears to be
confined to brain regions affected by AD and closely correlates
with NFT counts indicating a link between synaptic dysfunction
and tangle formation in AD patients (see Reddy and Beal, 2008;
Arendt, 2009).
Synaptic loss as measured by decreased levels of synapto-
physin and PSD-95 has been demonstrated in both immature and
mature rodents following TBI (Gobbel et al., 2007; Ding et al.,
2009; Wakade et al., 2010; Gao et al., 2011). The cognitive impair-
ment observed was closely associated with the degree of synaptic
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loss and recovery of cognitive performance following TBI corre-
lated with increased levels of synaptic marker proteins. PSD-95
is a scaffolding protein that plays an important role in synap-
tic maturation and plasticity associated with NMDA receptor
signaling. It has been demonstrated to control activity depen-
dent AMPA receptor incorporation at the synapse during LTP.
Due to its important role in maintaining synaptic plasticity and
strengthening LTP induction, its loss in the hippocampus has
been implicated in the cognitive deficits observed following TBI
and in AD (see Gobbel et al., 2007 and review Proctor et al., 2011).
Upregulation of members of the matrix metalloproteinase
(MMP) family, in particular MMP-9 a potent inflammatory
mediator, via HIF1α has been implicated in the loss of synapses
witnessed post-TBI. TBI-induced expression of HIF-1α leads to
synapse loss that closely correlates with the upregulation ofMMP-
2 and MMP-9. Synaptic loss was prevented by inhibiting HIF1α
expression andMMP-9 upregulation by the administration of the
anti-inflammatory drug minocycline (Ding et al., 2009). MMP’s
are a family of proteins that are involved in regulating extra-
cellular matrix proteins and under normal conditions play an
important role in synaptic plasticity and cognition. MMP-9 levels
have been demonstrated to increase concordantly with increasing
injury severity and play an important role in edema formation
following experimental TBI (see Copin et al., 2012). Additionally,
increased MMP-9 plasma levels are an important predictor of
length of hospital stay and death in severe TBI patients (see Copin
et al., 2012). The importance of MMP-9 to outcome following
TBI is reinforced by data demonstrating that MMP-9 knockout
mice suffer greatly reduced tissue and cell loss and improved
functional outcome following TBI (Wang et al., 2000). The role
of inflammation-induced increases of MMP-9 in the synaptic
dysfunction witnessed in AD is of particular interest as MMP-
9 levels are elevated in the plasma and brain of AD patients
(Lorenzl et al., 2003) and neuroinflammation is a feature of the
AD brain.
Aβ and in particular oligomeric Aβ species have been
demonstrated to play an important role in impairing LTP and
modulating synapse density and hence cognition in a variety
of experimental settings including hippocampal slice cultures
and transgenic mouse models (see Revett et al., 2013). Elevated
oligomeric Aβ levels in the hippocampus and cortex which occurs
during the progression of AD and following head injury could
play a role in mediating cognitive decline through disruption of
the excitatory glutamatergic synapses.
GLUTAMATE AND Aβ-MEDIATED EXCITOTOXICITY
FOLLOWING TBI AND IN AD BRAINS
Excessive NMDA receptor activation leading to excitotoxicity has
been implicated in the pathophysiology of both TBI and AD.
Chronic stimulation of NMDA receptors by glutamate or NMDA
has been demonstrated to alter APP processing and stimulate
Aβ production in neurons presumably through impaired calcium
homeostasis (Willoughby et al., 1995; Lesne et al., 2005). This is
supported by a strong correlation between Aβ level and neuronal
firing at excitatory synapses under normal conditions and follow-
ing TBI. This relationship is particularly evident in brain regions
vulnerable to Aβ deposition in ADmouse models (Buckner et al.,
2005; Cirrito et al., 2005, 2008; Brody et al., 2008; Marklund et al.,
2009; Schwetye et al., 2010; Bero et al., 2011).
The cellular pool of NMDA receptors activated plays an impor-
tant role in Aβ production and cell fate. Activation of synap-
tic NMDA receptors promotes the non-amyloidogenic pathway
reducing Aβ generation, upregulating ERK and CAMK pathways
thereby phosphorylating the cAMP responsive element protein
(CREB) promoting LTP as well as the upregulation of the prosur-
vival gene BDNF. Conversely, activation of extrasynaptic NMDA
receptors promotes the amyloidogenic pathway leading to Aβ
production and has been shown to downregulate phosphoryla-
tion of CREB and enhance LTD, while also inducing a loss of
mitochondrial membrane potential signaling activation of cell
death pathways (Hardingham et al., 2002; Bordji et al., 2010)
(Figure 4).
Elevated synaptic glutamate plays an important role in
oligomeric Aβ-mediated synaptic dysfunction (impairment of
LTP) and synaptic degeneration (see Revett et al., 2013).
Impairments in astrocytic glutamate uptake have been identi-
fied following TBI and in AD brains and may be responsible for
the increased synaptic glutamate that triggers NMDA-mediated
excitotoxicity. There is a transient reduction in glial glutamate
transporters GLAST (EAAT1) and GLT-1 (EAAT2) and the astro-
cytic splice variant GLT-1v (EAAT2b) in rodents (Rao et al., 1998;
Yi and Hazell, 2006) and humans (van Landeghem et al., 2006)
following TBI. These glutamate transporters handle the bulk of
extracellular glutamate uptake, resulting in increased extracellu-
lar glutamate levels that contribute to excessive NMDA receptor
activation and excitotoxicity. EAAT2 and EAAT2b levels are dra-
matically down regulated in the brains of AD patients (Scott
et al., 2011). In one study the presence of novel splice variants
of EAAT2 that had been shown to be non-functional in in-vitro
assays correlated with neuronal loss in AD brains (Masliah et al.,
1996; Li et al., 1997; Scott et al., 2011). Additionally, Aβ oligomers
have been shown to dramatically reduce the expression of EAAT2
in astrocytic cultures (Abdul et al., 2009) and there is evidence
that inflammatory cytokines such as TNFα can inhibit astro-
cytic glutamate transporters (see Pickering et al., 2005). Aβ or
inflammation-mediated impairments in glial glutamate uptake
may be amechanism contributing to chronic activation of NMDA
receptors following TBI and in AD. To this end a recent study by Li
et al. (2011b) has demonstrated that Aβ oligomers can interrupt
glutamate reuptake resulting in increased extracellular glutamate
which is capable of triggering extrasynaptic NR2B NMDA recep-
tor activity. This leads to inhibition of LTP and enhancement
of LTD through calpain and P38 MAPK pathway activation and
decreased CREB phosphorylation (Li et al., 2011b). The impor-
tance of the activation of the extrasynaptic pool of NMDA recep-
tors to Aβmediated excitoxicity and cognitive impairment could
explain an important reason why the success of NMDA antago-
nism in ameliorating cognitive dysfunction post-TBI in rodents
and AD transgenic mouse models could not be replicated in
human TBI patients and AD sufferers. Memantine, the only FDA
approved NMDA antagonist for the treatment of dementia, pri-
marily targets the pool of extrasynaptic NMDA receptors, thereby
allowing the beneficial effects of synaptic NMDA activation to
remain largely unaffected (Xia et al., 2010).
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FIGURE 4 | Schematic representation of potential molecular
mechanisms modulating Aβ and Tau pathology following injury. Loss of
neurons, synapses, and dendritic spines as well as elevated soluble Aβ
levels, amyloid plaque deposition along with elevated phosphorylated tau
levels and the formation of neurofibrillary tangles (NFT’s) are pathological
features common to both traumatic brain injury (TBI) and Alzheimer’s disease
(AD). Not surprisingly the pathophysiological mechanisms leading to cell
death, synaptic dysfunction and altered Aβ and tau pathology also overlap.
Glutamate mediated excitotoxicity is a key initiator of cell death following
traumatic brain injury (TBI). Excessive glutamate induced activation of
extrasynaptic NMDA receptors leads to dramatically elevated intracellular
calcium levels. Impaired calcium homeostasis in turn initiates a number of
crucial downstream cellular injury processes including mitochondrial oxidative
stress as well as the activation of the calcium sensitive proteases (caspases
and calpains) which have been demonstrated to induce cell death in vitro (and
hence loss of neurons and synapses) via caspase-3 activation and the
cleavage of tau into a 17 kDa toxic tau fragment. TBI induced inflammatory
events including activation of microglia and astrocytes and hence increased
cytokine and chemokine production plays an important role in cell death
following injury. Inflammation may amplify excitotoxic cell death by reducing
glial glutamate transporters leading increased glutamate at the synapse
exacerbating calcium dysgregulation. Experimental evidence suggests
calcium-induced activation of calpain and calcineurin induces dendritic spine
remodeling and loss and hence impairs synaptic transmission. Additionally,
calpain and calcinuerin have both been implicated in NFT formation via
cleavage induced activation of GSK-3β leading to hyperphosphorylation of
tau. TBI induces elevated levels of soluble Aβ which is capable of inducing
synaptic dysfunction. β-secretase (BACE1) is a key rate limiting enzyme in the
production of Aβ and we have demonstrated a molecular mechanism by
caspase-3 mediated depletion of the adaptor proteins GGA1 and GGA3
modulates BACE1 levels and Aβ production following experimental TBI.
Experimental evidence suggests that soluble Aβ is capable of directly
mediating many of the cellular injury processes characteristic of the
secondary phase of TBI and hence elevated Aβ levels may be key initiating
events in the development of a “feed forward” toxic cascade that links TBI to
chronic neurodegeneration.
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MITOCHONDRIAL DYSFUNCTION/OXIDATIVE STRESS IN
PATHOPHYSIOLOGY OF TBI AND AD
Impaired intracellular calcium homeostasis and the resultant
mitochondrial dysfunction and oxidative stress are pathophysio-
logical hallmarks of both TBI and AD. Mitochondrial oxidative
stress occurs early in AD progression and has been extensively
demonstrated in AD patients and AD transgenic mouse mod-
els (see Ansari and Scheff, 2010; Dragicevic et al., 2010; Reddy
et al., 2010). Traditionally, the calcium dysregulation occurring in
AD patients has been attributed to calcium loading due to ER-
stress and has been linked to familial mutations in the PSEN1
gene (see Supnet and Bezprozvanny, 2010). However, it has been
shown that Aβ oligomers can themselves dramatically alter intra-
cellular calcium levels (see Reese and Taglialatela, 2011). In vitro
studies in rat cortical neurons have shown that Aβ can increase
intracellular calcium levels via NMDA and AMPAR activation
leading to mitochondrial calcium overload. As is the case post-
TBI, this mitochondrial calcium overload triggers the opening of
the mPTP, resulting in loss of mitochondrial membrane potential
triggering ROS production and oxidative damage (Alberdi et al.,
2010) (Figure 4).
In addition to activating cell death pathways, oxidative stress
results in impaired functioning and transport of mitochondria
from the cell body to the synapse, decreasing synaptic function
and ultimately leading to neurodegeneration (Reddy and Beal,
2008). Aβ appears to play a direct role in mediating mitochon-
drial dysfunction and oxidative stress, as Aβ has been isolated
from mitochondrial membranes in human AD brains and trans-
genic ADmouse models (see Reddy and Beal, 2008). While several
studies have isolated Aβ directly from synaptosomal fractions of
brain mitochondria, indicating that it may play a direct role in
mitochondrial dysfunction that leads to synaptic damage (see
Reddy and Beal, 2008). Mitochondrial dysfunction and oxida-
tive stress appear to be important mechanisms affecting cognitive
outcome following TBI and in AD, the evidence suggests that Aβ
could directly mediate these secondary injury events resulting in
neurodegeneration (Figure 4).
CALCIUM DYSREGULATION INITIATES PHOSPHATASE AND
PROTEASE ACTIVATION FOLLOWING TBI AND IN AD
BRAINS:
CALCINEURIN ACTIVATION CAN MODULATE Aβ AND TAU PATHOLOGY
CaN is a calcium regulated phosphatase that has been shown
to be upregulated following TBI (Kurz et al., 2005a,b) and in
AD brains particularly in astrocytes surrounding Aβ plaques (Liu
et al., 2005; Wu et al., 2010). Under normal conditions CaN
plays an important role in regulating neurotransmitter release and
synaptic plasticity. However, following brain injury it has been
implicated in the loss of dendritic spines, impairment of learning
andmemory through dephosphorylation of CREB, inflammation
and oxidative stress through the expression of cytokines and NOS
and the induction of glial apoptosis (see Campbell et al., 2012a).
Campbell et al. (2012b) demonstrated in a rodent model of lat-
eral fluid percussion that TBI induced CaN activation results in a
cofilin dependent degradation of the cytoskeleton of the dendritic
spines leading to shrinkage/collapse and eventual loss. This den-
dritic spine degeneration could be prevented by CaN inhibition
(Campbell et al., 2012b). Increased CaN activity may also play
a role in the dendritic spine loss and synaptic alterations evi-
dent in the brains of AD patients (see Knobloch and Mansuy,
2008). Recently, Hudry et al. (2012) demonstrated a mechanism
by which Aβ induced CaN activation and mediated dendritic
spine loss and remodeling through activation of the nuclear tran-
scription factor of activated T-cells (NFAT) (Hudry et al., 2012).
Cognitive decline in AD patients has been strongly associated
with the expression of NFAT isoforms in particular NFAT3 whose
expression is strongly linked with inflammation (Abdul et al.,
2009). The neuroinflammatory effect of CaN is mediated through
dephosphorylation of NFAT which can promote astrocyte acti-
vation. The importance of this mechanism to AD pathology is
revealed in a study in APP/PS1 mice in which inhibition of CaN
and NFAT binding in astrocytes is sufficient to reduce glial acti-
vation and Aβ production and improve cognitive performance
and synaptic function (Furman et al., 2012). Dendritic spine
loss/impaired synaptic function through CaN activation provides
an important mechanism for cognitive decline observed in AD
patients and cognitive dysfunction following TBI.
CaN activity in AD brains has been shown to correlate with
NFT’s indicating that CaN activity may also play an impor-
tant role in tau pathology. As the tau that composes NFT’s is
hyperphosphorylated and the primary role of CaN is to dephos-
phorylate substrates this appears counter intuitive. However, it
has been proposed that as CaN is activated by the binding of
calmodulin and as CaN needs to bind to tau directly in order to
dephosphorylate it, calcium induced calmodulin binding could
interfere with CaN’s ability to bind to tau and thereby prevent
tau dephosphorylation. Additionally, CaN has been implicated in
playing a role in dephosphorylating and thereby activating GSK-
3β. As activated GSK-3β is involved in phosphorylating tau, this
provides another important mechanism by which CaN activation
could lead to elevated phospho-tau levels and potentially the for-
mation of NFT’s seen in the brains of TBI and AD patients which
correlates with synaptic dysfunction and cognitive impairment
(see Reese and Taglialatela, 2011) (Figure 4).
CALPAIN ACTIVATION CAN MODULATE Aβ AND TAU PATHOLOGY
Calpains are ubiquitous calcium sensitive proteases that under
normal conditions are transiently activated and involved in essen-
tial functions in the cell includingmaintaining synaptic plasticity,
protein turnover and cell signaling. However, when chronically
activated due to high levels of calcium and depletion of cal-
pastatin (via caspase-3 and calpain activation), an endogenous
inhibitor of calpains, they can contribute to synaptic dysfunction
and neuronal death following TBI and in AD. Calpain activa-
tion is a common pathological event in experimental models
of TBI. It has been robustly demonstrated in rodents using a
variety of injury techniques which give rise to both focal and
diffuse injuries including: FPI, controlled cortical injury, weight
drop, etc. Depending upon the type of injury distinct temporal
patterns of calpain activation occur. In focal injuries activation
occurs within minutes to hours, whereas it is delayed under
conditions of diffuse injury. Additionally, calpain activation has
been observed in human TBI subjects (see Vosler et al., 2008;
Saatman et al., 2010). In vitro and to a lesser extent in vivo studies
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have demonstrated that calpains cleave a number of substrates,
which may play key roles in cognitive dysfunction following TBI.
Calpains are capable of cleaving a variety of structural proteins,
receptors and channel proteins, signaling enzymes, apoptotic pro-
teins and transcription and translation initiation factors, resulting
in disruption of axonal transport, axonal degeneration, alter-
ations in signal transduction and cell death. Calpain inhibition
has been shown to be neuroprotective in a number of experi-
mental TBI studies (for a detailed review see Vosler et al., 2008;
Saatman et al., 2010).
Calcium-induced calpain activation along with reduced cal-
pastatin levels have been observed in the brains of AD patients
indicating calpain dysregulation. Evidence suggests that chronic
calpain activation can influence the formation of amyloid
plaques, NFT’s and the synaptic pathology that is observed
in AD brains (Ferreira, 2012). Aβ is able to activate calpains
through excessive NMDA receptor activation (see Ferreira, 2012).
Activated calpains cleave a number of neuronal proteins that are
involved in AD. It is possible that calpain activation in the brains
of AD patients impairs cognitive function by cleaving Protein
Kinase A thereby reducing CREB phosphorylation and attenu-
ating its activity and preventing the consolidation of short-term
memory to long-term. The attenuation of CREB activity can also
be mediated indirectly through calpain-mediated activation of
CaN A, levels of which correlate NFT’s in AD brains. Calpain has
been theorized to be involved in synaptic dysfunction by impair-
ing synaptic vesicle recycling due to cleavage of Dynamin 1, which
is reduced in AD brains (for a detailed review see Ferreira, 2012).
Calpain activation may also play a role in Aβ generation.
In vivo studies in the APP/PS1 transgenic mouse model of AD
showed that calpain activation resulted in dramatically increased
Aβ levels and plaque deposition and that this was most likely
mediated through elevations in BACE1 level and activity (Liang
et al., 2010). It may also play an important role in the hyper-
phosphorylation of tau by the cleavage and subsequent activation
of a number of kinases involved in tau hyperphosphorylation
including GSK-3β, Protein kinase C, calcium/calmodulin kinase
(CamK) IIα, p35 which activates Cdk5 (see Vosler et al., 2008).
Conversely, calpain inhibition through overexpression of calpas-
tatin in the APP/PS1 transgenic mouse model was found to
reduce amyloid beta plaques, prevent Tau hyperphosphorylation
(by preventing activation of Cdk5) and synapse loss. Importantly,
inhibition was found to prevent the calpain-induced decrease
in CREB phosphorylation and improve spatial memory in the
APP/PS1 mice (Liang et al., 2010). These results confirm those
obtained by Trinchese et al. (2008) who showed pharmacological
inhibition of calpain was able to restore normal synaptic func-
tion and improve spatial and fear associated memory in APP/PS1
mice (Trinchese et al., 2008). In addition to increasing Aβ levels
and hyperphosphorylating tau, calpain activation may also con-
tribute to AD pathology through the cleavage of Tau to generate a
17 kDa toxic tau fragment. High levels of this 17 kDa Tau frag-
ment have been found in the brains of AD patients as well as
patients with other tauopathies. While the role this Tau fragment
plays in neurodegeneration is not well understood, it has been
implicated in playing a role in tau aggregation and could promote
the formation of NFT’s (Vosler et al., 2008) (Figure 4).
CASPASE-MEDIATED APOPTOSIS FOLLOWING TBI AND IN AD BRAINS
Apoptosis can occur by multiple overlapping pathways. The cys-
teine protease family of caspases are well characterized effectors
of apoptotic cell death and hence apoptotic pathways are classi-
fied as caspase-dependent or caspase-independent (Zhang et al.,
2005). Caspase-dependent apoptosis has been implicated in the
synaptic dysfunction/degeneration and neuronal cell loss that
are hallmarks of both TBI and AD. Increased expression of cas-
pases and caspase activation (caspases −1, −3, −7, −8, −9
and−12) have been identified clinically (Clark et al., 1999; Zhang
et al., 2003, 2006; Darwish and Amiridze, 2010) and experimen-
tally (Keane et al., 2001; Knoblach et al., 2002; Larner et al.,
2004, 2005) following TBI with involvement of both the extrinsic
(TNF and Fas receptor mediated) and intrinsic (mitochondrial
mediated) apoptotic pathways (Minambres et al., 2008). There
is accumulating evidence implicating apoptosis and in particu-
lar caspase-mediated apoptosis in the disease progression and
pathology of AD (see reviews Castro et al., 2010; Rohn, 2010).
Despite early difficulties associated with identifying activated cas-
pases in postmortem AD brain tissue, evidence has been obtained
demonstrating activation of caspases in AD tissue in particular
the initiator caspases −8 and −9 and the effector caspases −3
and −6 (see refs Castro et al., 2010; Rohn, 2010). Additionally
a study by Pompl et al. (2003) found increased transcript lev-
els of both death associated as well as inflammation associated
caspases (−1, −2, −3, −5, −6, −7, −8 and −9) in the brains
of AD patients(Pompl et al., 2003). Caspases have been demon-
strated to be able to cleave two key molecules involved in AD
pathology, APP, and Tau, which could facilitate the production
of Aβ and the formation of NFT’s (see review Castro et al., 2010).
Caspase-3 activation is one of the most extensively characterized
mediators of cell death following TBI in humans and experi-
mental animal models. A study by Abrahamson and colleagues
demonstrated that administration of a pan-caspase inhibitor fol-
lowing CCI in rodents reduced caspase-3 activation and caspase
cleaved APP fragments and was associated with an inhibition of
TBI induced Aβ generation (Abrahamson et al., 2006). However,
the mechanism by which direct cleavage of APP leads to Aβ pro-
duction following TBI has not been conclusively demonstrated.
Gervais and colleagues proposed that caspase-mediated cleavage
of APP at APPD720 was responsible for increased Aβ gener-
ation associated with apoptosis (LeBlanc, 1995; Barnes et al.,
1998; Galli et al., 1998; Gervais et al., 1999; Guo et al., 2001;
Tesco et al., 2003; Sodhi et al., 2004). In contrast, our labora-
tory has shown that caspase activation can lead to increased Aβ
generation independently of APP cleavage in Chinese hamster
ovary (CHO) cells (Tesco et al., 2003). We subsequently showed
that caspase-3 cleavage of the adaptor protein GGA3 leads to
increased BACE1 levels and activity and increased Aβ produc-
tion following TBI in rodents (Walker et al., 2012). Our data
suggest that inhibition of caspase-3 activation may be benefi-
cial in reducing Aβ production by preventing caspase-mediated
depletion of GGA3 and the subsequent accumulation of BACE1
following TBI.
Activated caspase-3 has been identified in neurons within AD
brains and has been demonstrated to colocalize with NFT’s and
amyloid plaques (Su et al., 2001). Caspase activation has been
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implicated inNFT formation in AD brains via Tau cleavage. There
is increasing evidence that truncation of the tau protein is an
important event in promoting the aggregation of tau (see Lee
and Shea, 2012). C-terminal cleaved Tau (D421) has been iden-
tified in the brains of AD patients (see Lee and Shea, 2012). It
has been proposed that cleavage of tau at its C-terminus causes
a conformational alteration, which along with phosphorylation
contributes to the aggregation of tau into tangles (Lee and Shea,
2012). Evidence to support this idea has recently been obtained
via two-photon microscopy in a tau transgenic mouse model
(Tg4510), demonstrating that caspase-3 activation precedes tan-
gle formation. Importantly, the neurons in which caspase-3 acti-
vation occurred did not die acutely but instead developed tangles
(De Calignon et al., 2010). It has recently been demonstrated
that caspase-3 activation is an early event in a transgenic mouse
model of AD (Tg2576) that triggers synaptic dysfunction long
before deposition of Aβ plaques occurs in this model. In this
model caspase-3 activation resulted in a permanent activation of
CaN, which triggered the dephosphorylation and removal of the
post-synaptic AMPA receptor GluR1 subunit leading to impair-
ments in glutamatergic neurotransmission, which correlated with
spine degeneration in CA1 pyramidal neurons and impaired hip-
pocampal dependent memory formation (D’Amelio et al., 2011).
Additionally, activated caspase-3 is enriched in the post-synaptic
density within the brains of AD patients (Louneva et al., 2008).
When taken together with data from AD transgenic mouse mod-
els this indicates an important role for caspase-3 in AD related
synaptic degeneration. As a result, in addition to initiating apop-
tosis and neuronal loss following TBI and in AD brains, caspases
such as caspase-3 play important roles in synaptic dysfunction
and tau pathology that correlates with cognitive impairment
(Figure 4).
INFLAMMATION IN TBI AND AD
Inflammatory pathway activation has been implicated in medi-
ating secondary injury following acute brain injury as well as
in chronic neurodegeneration settings such as the brains of AD
patients. Widespread activation of microglia and astrocytes par-
ticularly in the vicinity of Aβ plaques has been observed in AD
brains and the severity of microglial activation has been linked to
the degree of brain atrophy and cognitive decline (Cagnin et al.,
2001; Parachikova et al., 2007; Ferretti et al., 2012). Activated
microglia and astrocytes have also been demonstrated in a vari-
ety of AD transgenic mouse models (Heneka et al., 2005; Noble
et al., 2010; Schwab et al., 2010; Ferretti et al., 2012). Importantly,
inflammatory markers including activated microglia and astro-
cytes are detected in the brain of AD transgenic mice prior
to Aβ plaque accumulation, indicating that inflammation is an
important initiating event in Aβ pathology (Heneka et al., 2005;
Schindowski et al., 2006; Garwood et al., 2010). The early acti-
vation of inflammation in AD disease pathogenesis explains why
non-steroidal anti-inflammatories (NSAID’s) have only shown
beneficial effects in reducing the risk of developing dementia in
patients who have not yet shown any signs of mild cognitive
impairment (the prodromal state of AD).
TBI has been shown to result in rapid activation of
microglia and astrocytes and is accompanied by the secretion of
inflammatory cytokines and chemokines including IL-1β, IL-6,
and TNF-α (Lloyd et al., 2008). Upregulation of IL-1β following
experimental TBI in rodents has been shown to occur concur-
rently with increases in APP and has been implicated in Aβ
production following injury (Ciallella et al., 2002). Inflammatory
cytokines as well as activated microglia and astrocytes have been
demonstrated to upregulate APP in vitro and in both wild-type
and transgenic mice (Brugg et al., 1995). This upregulation of
APP has been shown to increase Aβ levels, and in vivo studies
using transgenic mice indicate that inflammation could medi-
ate its effect on Aβ production through increased BACE1 levels
and activity (Sheng et al., 2003; Heneka et al., 2005; Lee et al.,
2008; Ferretti et al., 2012). It has been proposed that upregulation
of APP and BACE1 levels and activity by inflammatory media-
tors results in increased Aβ production, which in turn further
activates microglia creating a vicious cycle of neurotoxic events
leading to chronic neurodegeneration (Sastre et al., 2008). NFκB
a key transcription factor whose expression is increased post-
TBI can regulate the expression of several inflammatory markers
and has been implicated in the regulation of APP and BACE1 in
inflammatory settings (Ferretti et al., 2012). Evidence exists that
NFκB can regulate BACE1 in vivo, indicating that upregulation of
NFκB following TBI may be one potential mechanism by which
APP and BACE1 and hence Aβ increases are regulated post-TBI
(Figure 4).
The vast majority of research has focused on the role of
microglial activation in chronic neuroinflammation in the AD
brain and following TBI. While activated astrocytes have been
shown to play an important role in AD pathology in mouse
models, their role in TBI induced chronic neuroinflammation
has received less attention. This is due in part to the complex
dual neuroprotective and neurotoxic nature of astrocytic activa-
tion following TBI (see review Laird et al., 2008). Interestingly,
a recent study has shown that loss of activity of the dopamine
receptor DR2 (DRD2) in astrocytes leads to astrocytic activa-
tion and chronic neuroinflammation (Shao et al., 2012). DRD2
activity regulates the expression of the small heat shock protein
αB-crystallin which is neuroprotective and anti-inflammatory. A
polymorphism within the ANKK1/DRD2 region has been shown
to reduce the expression of DRD2 and is correlated with impaired
cognition post-TBI in humans (McAllister et al., 2008). While
the role of dopamine in inflammation following TBI is not well
understood this new data highlighting the role of DRD2 in medi-
ating inflammation may help to explain not only the beneficial
effects of DR2 agonists on cognitive performance following exper-
imental TBI but also the cognitive impairments witnessed follow-
ing administration of certain antipsychotics such as Haloperidol
which have been found to antagonize DRD2 (Wilson et al., 2003).
Chronic astrocytic activation has important implications for Aβ
generation in AD brains and following TBI. Traditionally, neu-
rons are thought of as the major sources of Aβ generation,
however, activated astrocytes may be an important source of Aβ
under conditions of stress such as cerebral injury. A recent study
by Zhao et al. (2011) demonstrates that the cytokines TNFα and
IFNγ which are secreted under inflammatory conditions such
as TBI are capable of increasing APP and BACE1 levels and
increasing β-secretase processing of APP generating increased
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Aβ in activated astrocytes. Additionally, they demonstrated that
oligomeric and fibrillar Aβ42 is also capable of increasing BACE1,
APP and APP processing suggesting a feed forward mechanism
driven by inflammation and Aβ42. This is a potentially important
source of Aβ under inflammatory conditions as astrocytes out-
number neurons 5-fold indicating a large source of Aβ that may
initiate downstream neurotoxic cascades (Zhao et al., 2011).
As is the case in AD brains inflammation is one of the ear-
liest pathways activated post-TBI and is also one of the most
persistent. In animal models of TBI inflammation has been
shown to persist for at least 1yr post injury (Acosta et al., 2013).
While, chronic neuroinflammation andmicroglial activation have
been demonstrated in human TBI patients up to 17 years post
moderate to severe TBI injury (Ramlackhansingh et al., 2011).
The development of chronic neuroinflammation following an
acute brain injury indicates that inflammatory mechanisms have
the potential to exacerbate Aβ production for prolonged peri-
ods following injury and provides an important link to chronic
neurodegeneration.
TBI AND CHRONIC TRAUMATIC ENCEPHALOPATHY
The increased risk of developing AD following TBI appears to be
associated with single events of moderate to severe injury inten-
sities. In comparison, CTE is a neurodegenerative disease that
appears to be associated with repetitive mild trauma. Originally
described in 1928 in boxers and termed dementia pugilistica
(Martland, 1928), the term CTE was coined in 1973 to describe
this neuropathological entity and to encompass those who devel-
oped it as a result of playing contact sports (Corsellis et al.,
1973).
CTE usually presents in mid-life and the early clinical man-
ifestations of CTE affect behavior including increased levels of
anger and irritability along with apathy. Cognitive dysfunction
presents with poor episodic memory and higher order execu-
tive functioning. The late stages of the disease are characterized
by movement and speech disorders. The lack of development of
full-blown dementia in the majority of CTE sufferers has been
attributed to the high suicide rates, which are a prominent feature
of the disorder (Gavett et al., 2011). CTE is considered to be the
signature injury pathology sustained in contact sports in the form
of concussion and sub-concussion, but has also been identified
in military personnel subjected to blast injury. Interestingly, in
contrast to the model of repetitive trauma over time put forward
for CTE, researchers have been able to replicate CTE pathol-
ogy in mice with a single a blast exposure (Goldstein et al.,
2012).
CTE is defined as a progressive tauopathy with TDP-43 pro-
teinopathy. Extensive tau immunoreactive NFT, neuropil neuri-
tis (NT), and glial tangles (GT) are found in the frontal and
temporal cortices. While the Tau detected in CTE biopsies is
hyperphosphorylated as occurs in AD and other tauopathies its
anatomical distribution is unique to CTE (Stern et al., 2011).
TDP-43 inclusions are widespread in CTE cases, a small sub-
set of CTE patients with TDP-43 inclusions in the anterior
horn of the spinal cord and motor cortex develop a progres-
sive motor neuron disease, providing further evidence that some
cases of ALS may be associated with TBI (McKee et al., 2010;
Stern et al., 2011). However, despite the generally accepted view
that the Tau accumulation observed in CTE occurs largely in
the absence of Aβ, many pathological studies have revealed the
presence of significant Aβ deposits in CTE cases. It has been
hypothesized that the presence of the APOε4 allele may be respon-
sible for modulating the pathology and hence the observed Aβ
in some cases of CTE (Dekosky et al., 2010). Like AD, the
presence of APOε4 appears to be an important genetic risk
factor the development of CTE (see Lakhan and Kirchgessner,
2012).
While the pathology of CTE has been well described, lit-
tle is known about the mechanisms by which, repetitive head
trauma can lead to chronic neurodegeneration. This has been
in part to due to the focus of most experimental TBI mod-
eling on single events of mild, moderate or severe TBI rather
than repetitive mild TBI events, and also due to the lack of
appropriate models of repetitive mild TBI that encompass the
rotational as well as linear acceleration/deceleration forces that
appear to be important in repetitive TBI pathogenesis (see Viano
et al., 2009). Newly described repetitive TBI models utilizing
rodents have been identified which recapitulate many of the
pathological hallmarks of repetitive TBI injuries in humans and
may facilitate the study of mechanisms responsible for CTE
(Shitaka et al., 2011; Kane et al., 2012; Mouzon et al., 2012;
Ojo et al., 2013). Recently, Blaylock and Maroon (2011) pub-
lished an interesting review proposing that the mechanism of
immunoexcitoxicity may play a key role in mediating the devel-
opment of CTE following repetitive TBI. This theory proposes
that the interaction between the immune receptors of the CNS
and the excitatory glutamate receptors that triggers a series of
injury events including: ROS/rNOS production, accumulation of
lipid peroxidation products and prostaglandin activation, which
then leads to dendritic retraction, synaptic injury, damage to
microtubules and mitochondrial suppression (see Blaylock and
Maroon, 2011, for a detailed review). Presumably, the mech-
anisms previously described that modulate tau pathology in
reference to AD such as CaN and calpain activation would
apply in the setting of CTE. However, as previously mentioned
while the pathology of CTE has been thoroughly described, the
lack of appropriate experimental models has somewhat ham-
pered the investigation of the molecular mechanisms. The recent
development of rodent models of repetitive injury that recapit-
ulate the pathology seen in human TBI patients should greatly
increase our understanding of the mechanisms leading to CTE
pathology.
COGNITIVE RESERVE AS A RISK MODIFIER FOR THE
DEVELOPMENT OF DEMENTIA FOLLOWING TBI
It is clear there are significant overlaps between the molecular
pathways including known genetic risk factors such as APOε4
that lead to cognitive dysfunction following TBI and in neurode-
generative diseases such as AD (Tables 1, 2). However, there still
remains the question of why only certain individuals with these
risk factors develop dementia following a brain injury. The idea of
“cognitive reserve” has been suggested to explain this discrepancy.
Cognitive reserve can be looked at as either a passive or active pro-
cess. A passive cognitive reserve process is where a certain amount
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Table 2 | Common pathophysiological mechanisms in TBI and AD.
Molecular dysfunction TBI (clinical and experimental) AD (human brain and transgenic mouse model)
Impaired synaptic plasticity
↓LTP ↑LTD
Albensi et al., 2000; Scheff et al., 2005 Oddo et al., 2003; Trinchese et al., 2004
Impaired glutamate transport
↓GLAST/EAAT1
↓GLT-1/EAAT2
Rao et al., 1998; van Landeghem et al., 2006;
Yi and Hazell, 2006
Masliah et al., 1996; Li et al., 1997; Scott et al.,
2011
↑NMDA receptor activation Palmer et al., 1993 Revett et al., 2013
Intracellular calcium dysregulation Sun et al., 2008; Saatman et al., 2010 See review Supnet and Bezprozvanny, 2010
Mitochondrial dysfunction Xiong et al., 1997; Gilmer et al., 2009 Dragicevic et al., 2010; Reddy et al., 2010
Oxidative stress Ansari et al., 2008; Cheng et al., 2012 Ansari and Scheff, 2010
Calcineurin activation Kurz et al., 2005a,b Liu et al., 2005; Wu et al., 2010
Calpain activation Vosler et al., 2008; Saatman et al., 2010 Trinchese et al., 2008; Ferreira, 2012
Apoptosis Minambres et al., 2008; Stoica and Faden,
2010
Castro et al., 2010; Rohn, 2010
Caspase-3 activation Clark et al., 2000; Stone et al., 2002;
Abrahamson et al., 2006; Walker et al., 2012
Tesco et al., 2007; see review Castro et al., 2010;
Rohn, 2010
↑BACE1 level and activity Blasko et al., 2004; Loane et al., 2009; Walker
et al., 2012
Fukumoto et al., 2002; Holsinger et al., 2002; Sun
et al., 2002; Tyler et al., 2002; Tesco et al., 2007;
Cole and Vassar, 2008
↓GGA3 and GGA1 adaptor
proteins
Walker et al., 2012 Tesco et al., 2007; Walker et al., 2012
Inflammation and chronic
microglial activation
Ramlackhansingh et al., 2011; Acosta et al.,
2013
Cagnin et al., 2001; Heneka et al., 2005;
Schindowski et al., 2006; Parachikova et al., 2007;
Garwood et al., 2010; Ferretti et al., 2012
of damage can be sustained before reaching a threshold level,
which results in symptoms. While an active cognitive reserve pro-
cess involves the brain actively attempting to compensate for the
damage (see for a detailed review Stern, 2002). TBI is thought
to accelerate the effects of aging by reducing cognitive reserve.
Individuals with a greater cognitive reserve are better able to cope
with the deleterious effects of a brain injury over the course of
aging either through active or passive processes, whereas, those
people with less cognitive reserve cannot. In view of the repetitive
nature of many TBI’s it is possible that a reduction in cognitive
reserve following the first injury can lead to the brain becom-
ing “primed” and any further insults to their brain may amplify
the deleterious effects of the original injury. These further insults
could encompass additional mild TBI’s or even lifestyle and envi-
ronmental exposures. Lifestyle factors such as poor health and
wellbeing due to poor diet leading to increased cholesterol lev-
els, a sedentary lifestyle, substance abuse etc may all contribute to
the deleterious effects of a brain injury (see Moretti et al., 2012).
Studies have shown that level of education and basal intelligence
level prior to injury are strongly associated with a protective effect
following injury. Additionally cognitive rehabilitation strategies
employed following TBI may protect against the risk of demen-
tia (see Moretti et al., 2012). Genetic factors (polymorphisms
in a wide variety of genes) can also play an important role
in cognitive reserve. While these studies are still at a relatively
early stage, polymorphisms have been identified in genes that are
important formodulating inflammatory responses, synaptic plas-
ticity, and repair mechanisms as well as catecholaminergic and
cholinergic function following neurotrauma (McAllister, 2010)
(see review Weaver et al., 2012). Of those studied so far in TBI
patients polymorphisms in Apolipoprotein E (APOE), catechol-
o-methyl transferase (COMT) and brain derived neurotrophic
factor (BDNF) genes have shown a significant correlation with
cognitive outcome following TBI (McAllister, 2010). Further
work needs to be performed to identify genetic variants involved
in the injury cascades that predispose patients to a worse outcome
following TBI that could predispose them to later development of
dementia (Figure 5).
CONCLUSIONS AND FUTURE DIRECTIONS
It is clear that there is significant overlap between the sec-
ondary injurymechanisms and pathology observed following TBI
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FIGURE 5 | Cognitive reserve as a risk modifier for cognitive
dysfunction and dementia following TBI. A number of environmental
and genetic factors determine a persons level of cognitive reserve, those
individuals with higher cognitive reserve are predicted to have a better
cognitive outcome and a reduced risk of developing dementia following
TBI. Individuals with lower cognitive reserve are predicted to have a
poorer cognitive outcome and an increased risk of developing dementia
following TBI. Cognitive reserve can be viewed as either an active
(inherent compensatory mechanisms) or a passive (level of damage that
can be tolerated by brain) process.
and in the brains of AD patients. These common mechanisms
include altered glutamatergic signaling, calcium dysregulation,
inflammation, mitochondrial oxidative stress, and apoptosis.
Importantly, it has been demonstrated that many of these pro-
cesses remain activated for prolonged periods of time following
injury, providing an important link between the acute injury and
the persistent cognitive impairments that have been observed
following TBI. Significant experimental evidence from in vitro
studies an in vivo animal models suggests that the activation of
these biochemical pathways could potentially modulate Aβ and
tau pathology. TBI has been demonstrated to lead to increased
Aβ production and there is evidence that the injury induced
modulation of BACE1 may play a key role in this increase. As
experimental evidence indicates that Aβ is able to directly mod-
ulate many of the neurotoxic biochemical pathways induced by
TBI, we postulate that Aβ may be the important link in initiat-
ing and sustaining a vicious neurotoxic cycle that leads to chronic
neurodegeneration.
However, in order to develop therapeutic interventions to
prevent or reverse the cognitive dysfunction observed following
TBI and in order to prevent the potential for development of
dementia later in life, additional research must be performed
to identify the molecular mechanisms that mediate the activa-
tion of these neurotoxic biochemical pathways. This will involve
utilizing transgenic and knockout mice or the development
of highly specific inhibitors that target molecular pathways of
interest such as those implicated in neuro-inflammation fol-
lowing TBI. The need for a more thorough understanding of
the molecular mechanisms linking TBI and chronic neurode-
generation is exemplified by the case of CTE. While there is
evidence supporting a solid link between a history of repeti-
tive mild TBI and the development of CTE and the pathol-
ogy has been well characterized very little is known about the
mechanisms that lead to this altered tau pathology. The devel-
opment of new experimental animal models of repetitive TBI
that more closely replicate CTE pathology along with detailed
biochemical analysis of the brains of CTE patients will facili-
tate this.
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